1. Home
  2. CPOP vs INAB Comparison

CPOP vs INAB Comparison

Compare CPOP & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pop Culture Group Co. Ltd

CPOP

Pop Culture Group Co. Ltd

HOLD

Current Price

$0.29

Market Cap

18.8M

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.83

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPOP
INAB
Founded
2007
2016
Country
China
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.8M
15.6M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
CPOP
INAB
Price
$0.29
$1.83
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
48.2K
58.5K
Earning Date
11-17-2025
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.13
52 Week High
$2.60
$4.20

Technical Indicators

Market Signals
Indicator
CPOP
INAB
Relative Strength Index (RSI) 50.04 65.57
Support Level $0.21 $1.52
Resistance Level $0.35 $1.81
Average True Range (ATR) 0.03 0.10
MACD -0.00 0.02
Stochastic Oscillator 60.76 89.77

Price Performance

Historical Comparison
CPOP
INAB

About CPOP Pop Culture Group Co. Ltd

Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: